KIORA PHARMACEUTICALS INC
KPRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $16.0M | $0 | — | $0 | $12,059 |
| Operating income | −$12.8M | $4.5M | −$12.6M | −$12.3M | −$16.9M | −$8.2M |
| Net income | −$10.8M | $3.6M | −$12.5M | −$13.6M | −$16.4M | −$8.1M |
| Total assets | $24.3M | $36.5M | $13.7M | $18.7M | $18.1M | $15.2M |
| Total liabilities | $8.1M | $10.7M | $7.6M | $7.3M | $8.8M | $8.2M |
| Equity | $16.1M | $25.8M | $6.1M | $11.4M | $9.2M | $7.0M |
| EPS (diluted) | $-2.64 | $0.87 | $-24.25 | $-18.55 | $-1.77 | $-1.77 |
| Shares out. | 3.0M | 26.3M | 1.9M | 12.7M | 7.1M | 4.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −67.2%
- Return on assets
- −44.7%
- Return on capital (ROCE)
- −62.2%
- Liabilities / assets
- 33.5%
- Debt / equity
- 0.50×
- Book value / share
- $5.37
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- −401.4%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -17.30distress
- Accruals / assets
- −3.6%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2022
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Recruitingreadout ~2026-11Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
- Phase 2Recruitingreadout ~2027-08A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Alyeska Investment Group, L.P.Passive (13G)May 15, 2026
- Nantahala Capital Management, LlcPassive (13G)May 15, 2026
- Nantahala Capital Partners Limited PartnershipPassive (13G)May 15, 2026
- Rosalind Advisors, Inc.Passive (13G)Feb 11, 2026
- Hirschman OrinPassive (13G)Jan 29, 2026
- Adar1 Capital Management, LlcPassive (13G)Aug 14, 2025
- Goldman Sachs Group IncPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 21,999 | 1.0 | -28.6% |
| Apr 30, 2026 | 30,793 | 1.0 | +7.5% |
| Apr 15, 2026 | 28,659 | 1.0 | +69.1% |
| Mar 31, 2026 | 16,951 | 1.0 | +7.4% |
| Mar 13, 2026 | 15,786 | 1.0 | +94.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 8, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureApr 7, 2026
- Director / officer change · Regulation FD disclosureApr 2, 2026
- Results of operationsMar 25, 2026
- Results of operationsNov 7, 2025
- Regulation FD disclosureAug 13, 2025
- Results of operationsAug 8, 2025
- Shareholder voteJun 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 424B3May 28, 2026
- EFFECTMay 22, 2026
- S-3May 18, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 8-KMay 8, 2026
- 10-QMay 8, 2026
- ARSARS - 10-KMay 1, 2026
- DEF 14AApr 30, 2026
- DApr 21, 2026
- 8-KApr 7, 2026
- 4FORM 4Apr 2, 2026
- 4FORM 4Apr 2, 2026
- 4FORM 4Apr 2, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.